SAN DIEGO--(BUSINESS WIRE)--Reveal Biosciences, Inc., a leader in pathology AI, announces today that it has closed a Series A financing round led by Intel Capital with additional investment from the GNI Group and PP Capital. Reveal is focused on improving global healthcare by creating a new generation of objective, data-powered pathology to characterize and detect disease.
Reveal will use the capital to expand its ImageDx™ online software platform with a growing pipeline of AI-based decision support tools. This cutting-edge technology focuses on objective data to help researchers make better decisions developing new therapies, and clinicians make better decisions for their patients.
“ImageDx has broad application within pathology for research, clinical trials, and healthcare,” said Claire Weston, PhD, Founder & CEO. “To date, ImageDx technology has delivered data to over 300 leading biopharma companies and academic institutions. Our integrated data-powered lab services uniquely position the company to generate high-performing pathology algorithms at scale. With this investment, we’re excited to expand our ecosystem of leading researchers, pathologists, and technologists to work together to lead the field toward this new paradigm.”
“AI is an accelerating technology within healthcare imaging that has already demonstrated significant potential to impact research and benefit patients,” said Naveen Rao, corporate vice president and General Manager of the Artificial Intelligence Products Group at Intel Corporation.” Senior Director Ranjeet Alexis led the investment for Intel Capital and will join Reveal’s board.
Reveal’s team brings together a unique blend of pathologists, including advisory representation by pathologists at ProPath Services, researchers, data scientists, and software professionals to lead the pathology market in data-powered decision making. Reveal Biosciences has been engaged in the development and commercialization of advanced tissue technologies and services since it was founded in 2012.
About Reveal Biosciences
Reveal Biosciences is focused on improving global healthcare by creating a new generation of objective, data-powered pathology to characterize and detect disease. With extensive scientific and computational expertise, the company is uniquely positioned to lead the digital pathology revolution. Our proprietary deep-learning platform, ImageDx™, delivers pathologists and scientists a novel class of actionable, quantitative data to advance research and enhance patient care. Reveal’s integrated data-powered lab services have accelerated research for over 300 leading biopharma and academic institutions to date. This advanced laboratory uniquely positions the company to deliver high performing pathology artificial intelligence algorithms at scale. For more information visit revealbio.com or follow @RevealBio.
About Intel Capital
Intel Capital invests in innovative startups targeting artificial intelligence, autonomous technology, data center and cloud, 5G, next-generation compute, and a wide range of other disruptive technologies. Since 1991, Intel Capital has invested US$12.4 billion in 1,554 companies worldwide, and 670 portfolio companies have gone public or participated in a merger or acquisition. Intel Capital curates thousands of business development introductions each year between its portfolio companies and the Global 2000. For more information on what makes Intel Capital one of the world’s most powerful venture capital firms, visit www.intelcapital.com or follow @Intelcapital.